PMID- 36532775
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221222
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - The safety and efficacy of esketamine in comparison to dexmedetomidine during 
      drug-induced sleep endoscopy in children with obstructive sleep apnea hypopnea 
      syndrome: A randomized, controlled and prospective clinical trial.
PG  - 1036509
LID - 10.3389/fphar.2022.1036509 [doi]
LID - 1036509
AB  - Background and Purpose: Data and high-quality studies of anesthetic methods for 
      children with obstructive sleep apnea hypopnea syndrome (OSAHS) who undergo 
      drug-induced sleep endoscopy (DISE) are limited. Research on pediatric DISE using 
      esketamine has never been reported before. To test the safety and efficacy of 
      esketamine during DISE in children with OSAHS, we compare esketamine (Group K) 
      with dexmedetomidine (Group D) in this study. Methods: 100 children with ASA Ⅰ approximately Ⅱ 
      grade, prepared for an elective adenotonsillectomy under general anesthesia, were 
      enrolled in this study and randomized into two groups. Midazolam 0.1 mg/kg was 
      administered intravenously for both groups. In Group D a 1 mug/kg bolus of 
      dexmedetomidine was given over 10 min followed by the infusion rate 1 mug/kg/hr to 
      the end of DISE. Group K received a 1.0 mg/kg IV bolus of esketamine over 10 s 
      followed by the infusion rate 1 mg/kg/hr to the end of DISE. Results: Group K had 
      a higher percentage of success than Group D (p = 0.008). The onset time of Group 
      K was shorter than that of Group D (p = 0.000). The University of Michigan 
      Sedation Scale (UMSS) score of Group K was higher than that of Group D (p = 
      0.005). The risk of adverse effects (AEs) was lower in Group K (p = 0.000). In 
      Group D, systolic and diastolic blood pressure (SBP and DBP) and heart rate (HR) 
      all decreased, while in Group K, SBP, DBP, and HR hardly changed. Conclusion: 
      Esketamine in comparison to dexmedetomidine provides more effective and safer 
      depth of anesthesia for OSAHS pediatric DISE by ensuring short onset time, deep 
      sedation, and few AEs. Clinical Trial Registration: ClincalTrials.gov, identifier 
      NCT04877639.
CI  - Copyright (c) 2022 Yongping, Xinyi, Aming, Qiang, Tianqi, Mengmeng, Xiong and 
      Xuemin.
FAU - Yongping, Zheng
AU  - Yongping Z
AD  - Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, 
      Hubei, China.
FAU - Xinyi, Li
AU  - Xinyi L
AD  - Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, 
      Hubei, China.
FAU - Aming, Sang
AU  - Aming S
AD  - Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, 
      Hubei, China.
FAU - Qiang, Xie
AU  - Qiang X
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Zhongnan Hospital of 
      Wuhan University, Wuhan, Hubei, China.
FAU - Tianqi, Zhou
AU  - Tianqi Z
AD  - Postanesthesia Care Unit, Department of Anesthesiology, Zhongnan Hospital of 
      Wuhan University, Wuhan, Hubei, China.
FAU - Mengmeng, Shen
AU  - Mengmeng S
AD  - Postanesthesia Care Unit, Department of Anesthesiology, Zhongnan Hospital of 
      Wuhan University, Wuhan, Hubei, China.
FAU - Xiong, Chen
AU  - Xiong C
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Zhongnan Hospital of 
      Wuhan University, Wuhan, Hubei, China.
FAU - Xuemin, Song
AU  - Xuemin S
AD  - Department of Anesthesiology, Research Centre of Anesthesiology and Critical Care 
      Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT04877639
PT  - Journal Article
DEP - 20221201
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9751969
OTO - NOTNLM
OT  - dexmedetomidine
OT  - drug-induced sleep endoscopy (DISE)
OT  - esketamine
OT  - obstructive sleep apnea hypoapnea syndrome
OT  - pediatrics
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/20 06:00
MHDA- 2022/12/20 06:01
PMCR- 2022/12/01
CRDT- 2022/12/19 04:21
PHST- 2022/09/04 00:00 [received]
PHST- 2022/11/18 00:00 [accepted]
PHST- 2022/12/19 04:21 [entrez]
PHST- 2022/12/20 06:00 [pubmed]
PHST- 2022/12/20 06:01 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - 1036509 [pii]
AID - 10.3389/fphar.2022.1036509 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Dec 1;13:1036509. doi: 10.3389/fphar.2022.1036509. 
      eCollection 2022.